Strategic Diagnostics' Antibody Revenue Gains Tempered by Ag/GMO Decline

Nov 02, 2007

NEW YORK (GenomeWeb News) — Strategic Diagnostics today said third-quarter revenues were flat as R&D spending rose 9 percent and profit fell around 70 percent.

Total receipts for the three months ended Sept. 30 dipped slightly to $6.56 million from $6.62 million year over year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Breakthrough Prize Winners Announced

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

Misuse of Genetic Research

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Not Quite the Ivy League Gene

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

This Week in Nature

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Main menu